Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 44c
May 10, 2022 4:00 PM EDTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of $0.41, $0.44 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $151.81 million versus the consensus estimate of $112.72 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
... More